Table 2.

Statistical analyses of pharmacokinetic parameters in Study 20110216

ComparisonGeometric mean ratio (90% CI)a
CMaxAUC0-tAUC0-Inf
ABP215 vs. U.S.-licensed Avastin98.1 (93.7–102.8)98.3 (94.0–102.9)98.3 (94.0–102.9)
ABP215 vs. EU-approved bevacizumab102.9 (98.2–107.8)95.6 (91.3–100.0)95.6 (91.3–100.0)
U.S.-licensed Avastin vs. EU-approved bevacizumab104.9 (100.1–109.9)97.2 (92.8–101.7)97.2 (92.8–101.7)
  • aDenoted as percentage.